AKTS – aktis oncology, inc. - common stock (US:NASDAQ)
Stock Stats
News
Aktis Oncology to Present at Upcoming March Investor Conferences
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $31.00 price target on the stock.
Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $34.00 price target on the stock.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.